ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

zabadinostat

Also written as “Zabadinostat (CXD101)” and “CXD101 in Combination With Nivolumab”.

Its studies are mostly in Pancreatic Neoplasms · Colonic Neoplasms, led by 2 companies.

Drug pageZabadinostat: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jun 19, 20192 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Celleron Therapeuticsits history only10 open or runningphase 2since Jun 19, 2019Jun 19, 2019none ahead
ImmunityBio10 open or runningphase 1since Nov 20, 2025Nov 20, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of ImmunityBio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 21, 2022Named zabadinostatINNProposed as its International Nonproprietary Name in WHO's List 127
  2. Nov 20, 2025First study: phase 1 study in Pancreatic NeoplasmsFirst studyNCT07488884

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study ImmunityBio leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07488884Pancreatic Neoplasms1WithdrawnJun 1, 20270

How it is read

Names in the registry

  • “Zabadinostat (CXD101)”, 1 entry
  • “CXD101 in Combination With Nivolumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.